Introduction
Although deterioration in renal function is one of the most important co-morbidities 1 and often complicates the natural course of hospital stay in patients with acute heart failure (AHF), the terminology and optimal assessment of renal function in this clinical condition remain controversial. 2 In everyday practice, serum creatinine is used to monitor renal function, with a rise in its level traditionally considered as indicating worsening renal function (WRF) and linked with inevitably poor outcomes. 3 However, the results of recent studies have challenged this approach, showing that not every increase in serum creatinine levels in AHF indicates kidney injury/dysfunction with unfavourable consequences.
observations have led to the novel concept of interpretation of changes in renal biomarkers and proposal of new terminology to differentiate true WRF and pseudo-WRF, only the former being associated with an adverse clinical course. 6, 7 It seems appealing to characterize patients who develop true WRF and identify predictors of true WRF. New renal biomarkers typically applied for an early and specific diagnosis of kidney injury, enabling differentiation between structural nephron damage and impaired renal haemodynamics, may appear useful. 8 In this context, urinary biomarkers of tubular damage such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cystatin C (CysC) are particularly attractive. 9, 10 Elevated urinary levels of these molecules seem much less affected by their extra-renal synthesis and reflect either impaired reabsorption or increased production in the nephron segments. 11 There are a few reports regarding urinary NGAL and KIM-1 levels for prediction of WRF in the setting of AHF, with inconclusive results, most probably due to broad definition, based only on laboratory markers (creatinine).
12 -14 Interestingly, elevated serum levels of NGAL were linked with poor outcomes in patients with heart failure (HF), 15, 16 but the prognostic aspect of urinary levels of KIM-1 and CysC has not been studied.
We therefore set up a study, the main aim of which was to evaluate the predictive value of the serial assessment of the urinary levels of these novel biomarkers for the development of true WRF during a hospital stay of patients with AHF. We also investigated their predictive value for long-term outcome.
Methods

Study population
Patients hospitalized for AHF at the Centre of Heart Diseases, 4th Military Hospital, Wroclaw, Poland, between September 2010 and July 2012 were enrolled in the study. The inclusion criteria were: (i) age ≥18 years; (ii) a diagnosis of AHF as the primary cause of hospitalization [the diagnosis was based on the European Society of Cardiology (ESC) Guidelines criteria 17 -19 ] ; and (iii) patient's written agreement to participate. Exclusion criteria comprised (i) clinical diagnosis of concurrent acute coronary syndrome; (ii) cardiogenic shock; (iii) end-stage renal disease requiring renal replacement therapy (or planned renal replacement therapy); (iv) exposure to nephrotoxic agents; and (v) evidence of urinary infection or bacteraemia.
Patients were treated in accordance with the recommendations of the ESC Guidelines.
17,18 A treatment regimen was not controlled by the protocol and was left to the physicians' discretion. However, it was requested by the study protocol to collect all this information. The study protocol was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki. 20 
Study design
After confirmation of the diagnosis of AHF, patients were admitted and information on demographics, clinical history, co-morbidities and previous therapies was collected. In all patients within the first 4 h after admission, venous blood and urine samples were obtained for baseline measurements (see below). Serum creatinine measurements were repeated daily at days 2 and 3 and at discharge. were collected daily at days 2 and 3. After centrifuging, the plasma and urine were immediately frozen at −70 ∘ C until further laboratory analysis.
Worsening renal function
Worsening renal function was defined as a ≥0.3 mg/dL increase in serum creatinine or a >25% decrease in the estimated glomerular filtration rate [eGFR; calculated in mL/min/1.73 m 2 from the Modification of Diet in Renal Disease equation (MDRD)] 21 from the baseline value during the entire hospital stay. Patients who developed WRF were differentiated into those with 'true WRF' vs. 'pseudo-WRF'. The former group was defined as: presence of deterioration or no relevant improvement in clinical status despite optimized therapy during hospital stay (including those who died in hospital or had intensification in the therapy including vasoactive therapies, ultrafiltration, or renal replacement). The remaining patients who demonstrated only isolated changes in creatinine/eGFR have been classified as having pseudo-WRF.
Outcomes
Patients were seen after hospital discharge by the study investigators in the outpatient HF clinic with follow-up ≥12 months in all survivors. Information regarding survival was obtained directly from patients or their relatives, from the HF clinic database, or from the hospital system. No patient was lost to follow-up. The endpoint was all-cause death. The length of follow-up of survivors and patients in whom an event occurred after 12 months was censored at 365 days.
Biomarker assays in peripheral blood and urine
The analysis of urinary levels of KIM-1 (pg/mL) (uKIM-1), NGAL (pg/mL) (uNGAL), and CysC (pg/mL) (uCysC) was based on a new diagnostic platform from Singulex, Inc. (Alameda, CA, USA) with the Erenna immunoassay system which uses a microparticle immunoassay and single-molecule counting in a capillary flow system. Absolute urinary biomarker levels were normalized to the urinary creatinine, and ratios were expressed per g of creatinine (ng/gCr for uKIM-1 and μg/gCr for uNGAL and uCysC). The following laboratory parameters were assessed in all patients using standard methods in our laboratory: (i) blood count: haemoglobin (g/dL), leucocytes (10 9 /L), platelets (10 9 /L); (ii) serum creatinine (mg/dL) and urea (mg/dL); (iii) electrolytes: sodium (mEq/L), potassium (mEq/L); (iv) urine albumin to creatinine ratio (UACR, mg/g); (v) liver function: bilirubin (mg/dL), aspartate transaminase (AST; IU/L), alanine transaminase (ALT; IU/L); (vi) plasma NT-proBNP (pg/mL) was measured using electrochemiluminescence on the Elecsys 1010/2010 System (Roche Diagnostics GmbH, Mannheim, Germany); and (vii) high-sensitivity cardiac troponin I (hs-cTnI, ng/mL) using chemiluminescence (technology LOCI) on the Dimension EXL System (Siemens Healthcare Diagnostics, Erlangen, Germany).
Statistical analysis
Normally distributed continuous variables were presented as means ± standard deviations (SDs). The intergroup differences were tested using Student's t-test, the Mann-Whitney U-test, and analysis of variance (ANOVA). Variables with a skewed distribution were expressed as medians with lower and upper quartiles, and were log transformed in order to normalize their distributions. The categorical variables were expressed as numbers with percentages. The intergroup differences were tested using the 2 test. The associations between variables were assessed using univariate Pearson's correlation coefficients. The associations between WRF and clinical and laboratory variables were tested using univariable and multivariable logistic regression models. The variables that predicted development of true WRF in the univariable analysis were included in the multivariable model. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated through logistic regression analysis and evaluated according to the likelihood ratio test. The predictive value of uNGAL, uKIM-1, and uCysC for true WRF was assessed by the use of a receiver operating characteristic (ROC) curve analysis, thereby creating an optimal cut-off point. The Cox proportional hazards model was used to calculate the hazard ratio (HR) with corresponding 95% CI for all-cause mortality. A P value of < 0.05 was considered statistically significant. Statistical analysis was performed using the STATISTICA 10 data analysis software system (StatSoft, Inc.).
Results
Study population
One hundred and thirty-two patients were enrolled in the study with a mean age of 65 ± 13 years; 78% were male. Baseline characteristics and laboratory values of the study population are shown in Table 1 . During hospitalization, all patients received i.v. loop diuretics, 53 (40%) received a vasodilator (nitroglycerine), and 13 (10%) received an inotropic agent (dobutamine or dopamine), respectively.
The relationship between urinary biomarkers and other measures of kidney function
Baseline levels of the urinary biomarkers in the entire population were as follows (medians with lower and upper quartiles): uNGAL, 15.2 (7.2-41.2) μg/gCr; uKIM-1, 766 (240-1820) ng/gCr; and uCysC, 42.9 (10.1-106.9) μg/gCr, respectively. There were 67 (51%) patients with an eGFR <60 mL/min/1.73 m 2 on admission. There was no difference in the levels of uKIM-1, uNGAL, and uCysC in patients with eGFR <60 vs. ≥60 mL/min/1.73 m 2 . The levels of urinary biomarkers at baseline were moderately correlated with each other and with the UACR. There was no correlation between serum creatinine, eGFR, urea, and the new urinary biomarkers ( Table 2 ).
Prevalence and characteristics of patients with true worsening renal function
'True WRF' occurred in 13 (10%), 'pseudo-WRF' in 15 (11%), whereas the remaining 104 (79%) patients did not develop WRF. Clinical and laboratory characteristics of these three groups are presented in Table 3 . Patients with 'true WRF' were more often females, had higher levels of NT-proBNP, creatinine, and urea on admission, higher UACR at day 2, higher urea at day 3, higher . 
Urinary biomarkers as predictors of true worsening renal failure
In the multivariable model, baseline uNGAL, uNGAL at day 2, uNGAL at day 3, and uKIM-1 at day 2 remained significant predictors of true WRF after adjustment for other prognosticators ( Table 4 ). The ROC analysis for the concentration of uNGAL (Figure 1) . The optimal cut-off values were as follows: for baseline uNGAL, 29.2 μg/gCr (sensitivity 77%, specificity 69%); for uNGAL at day 2, 24.4 μg/gCr (sensitivity 91%, specificity 69%); for uNGAL at day 3, 32.5 μg/gCr (sensitivity 73%, specificity 78%); and for uKIM-1 at day 2, 1510 ng/gCr (sensitivity 80%, specificity 66%).
Length of hospital stay
The median (with lower and upper quartiles) length of hospital stay, after excluding the patients who died during hospitalization, was 7 (6-11) days. Patients with true WRF were hospitalized for 7 (6-13) days, those with pseudo-WRF for 4 (4-12) days, and those without WRF for 7 (6-11) days (P = 0.144). Patients with longer length of stay (above the median) had higher levels of creatinine and urea on admission: 1.3 (1.0-1.6) vs. 
Mortality
During the 1-year follow-up there were 36 (27%) deaths, made up of 5 (38%) deaths in patients with true WRF, 2 (13%) of those with pseudo-WRF, and 29 (28%) of those without WRF (P = 0.32).
In the univariable Cox model, elevated uNGAL on admission, at days 2 and 3 were associated with an increased risk of death (HR 1.29, 95% CI 1.00-1.67, P = 0.050; HR 1.29, 95% CI 1.04-1.60, P = 0.018; and HR 1.32, 95% CI 1.03-1.70, P = 0.026, respectively; units used for Cox model: 1 Ln μg/gCr). Similarly, elevated uCysC measured at day 2 was related to higher mortality (HR 1.35, 95% CI 1.08-1.68, P = 0.007; units used for Cox model: 1 Ln μg/gCr). Adjustment for the other prognosticators which appeared significant in univariable analysis (systolic blood pressure, catecholamine use, baseline NT-proBNP, and urea levels) was performed. Elevated levels of uNGAL on admission (HR 1.39, 95% CI 1.03-1.87, P = 0.031), at day 2 (HR 1.35, 95% CI 1.04-1.74, P = 0.022), and at day 3 (HR 1.45, 95% CI 1.09-1.92, P = 0.011), and uCysC at day 2 (HR 1.34, 95% CI 1.08-1.68, P = 0.009) were the predictors of mortality (units used for Cox model: 1 Ln μg/gCr). The levels of uKIM-1 at all analysed time points did not predict mortality.
Discussion
This study applies the new definition of WRF, placing the interpretation of the changes in creatinine/eGFR in the context of the clinical status of patients with AHF. With such an approach, the key finding of our study is that ∼10% of all AHF patients developed true WRF defined as a rise in creatinine/drop in eGFR accompanied by an adverse clinical course. Female gender, elevated NT-proBNP, less frequent use of ACE inhibitors/ARBs, but mainly changes in renal biomarkers characterized this group. Importantly, patients with pseudo-WRF, defined as having only an increase in creatinine with an uneventful clinical course, did not differ from those without WRF.
Neither the prevalence nor the predictors of true WRF found in our study can be directly compared with other reports as they used a 'traditional' definition of WRF based solely on serial assessment of creatinine levels. However, looking at the total number of patients who developed an increase in creatinine levels fulfilling the widely used definition of WRF used in the literature (i.e. an increase of ≥0.3 mg/dL during hospital stay), we identified 21% of such patients in our AHF cohort, which is comparable with the prevalence of WRF previously reported. 3 Importantly, splitting these patients into two categories, i.e. those with true WRF vs. those with pseudo-WFR, we found an approximately equal number of patients in each category. Only the former group differed significantly from patients who did not experience any rise in creatinine/drop in eGFR. We believe that this is a relevant finding supporting the concept proposed by Damman and Testani to combine changes in renal function measures with clinical response in order to distinguish and characterize patients developing kidney AF, atrial fibrillation/flutter; ALT, alanine transaminase; AST, aspartate transaminase; BP, blood pressure; Cr, creatinine; DM, diabetes mellitus; GGTP, -glutamyltranspeptidase; HF, heart failure; HFrEF, heart failure with reduced ejection fraction (<40%); JVP, jugular venous pressure; LD, loop diuretic; MAP, mean arterial pressure; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; TnI, troponin I; UACR, urine albumin to creatinine ratio; uCysC, urinary cystatin C; uKIM-1, urinary kidney injury molecule-1; NGAL, urinary neutrophil gelatinase-associated lipocalin; WBC, white blood cell; WRF, worsening renal function. Data are presented as odds ratios (95% confidence intervals). Units for logistic regression models: gender, women vs. men; ACE inhibitor/ARB, yes vs. no; creatinine, 1 Ln mg/dL; NT-proBNP, 1 Ln pg/mL; uNGAL, 1 Ln μg/gCr; uKIM-1, 1 Ln ng/gCr. UACR, urine albumin to creatinine ratio; uNGAL, urinary neutrophil gelatinase-associated lipocalin; uKIM-1, urinary kidney injury molecule-1.
injury (and true cardio-renal syndrome type I) during the natural course of AHF. 7 In fact, only patients with true WRF demonstrated impaired baseline renal function (as evidenced by elevated serum creatinine and urea) but, more importantly, also significantly higher urinary levels of new biomarkers sensitive to detect renal tubular injury, which we believe is a relevant finding of our study. The urinary levels of NGAL were constantly elevated and remained fairly stable at all time points, whereas uKIM-1 levels were borderline elevated at baseline and rose further at day 2-which may indicate tubular injury being present already on admission with further . proved that evaluation of uNGAL at baseline and 12-24 h after initial therapy predicts WRF. Importantly, in this study, elevated uNGAL after 12-24 h was related to 30-day events. 22 In contrast,
Verbrugge et al. 13 were not able to show that uNGAL levels predicted WRF in the clinical setting of AHF, and Dupont et al.
kidney injury. Conflicting results reported here seem to be partially related to the fact that these authors combined patients with and without renal injury (true and pseudo-WRF, respectively), which explains the lack of difference in urinary levels of biomarkers and provides further argument to differentiate between these two groups. Additionally, our analysis was based on a new diagnostic platform using a highly sensitive immunoassay which allows precise detection of low levels of urinary biomarkers. We believe that the evaluation of new biomarkers in the course of hospitalization, measured with this sensitive assay, may have higher utility in the prediction of kidney injury and true WRF. In AHF, renal tubular damage may occur, which, in the condition of preserved renal functional reserve, would affect neither creatinine nor eGFR levels. 23, 24 This phenomenon is not yet well characterized in AHF, but some authors report that it may be driven by intense decongestion (insufficient renal perfusion due to aggressive volume depletion with diuretics as the mechanism) and/or haemodynamic derangements due to reduced renal perfusion. 25 Interestingly, in our study, neither the dose of diuretics used in the first 48 h nor clinical characteristics were different in patients with true WRF. In AHF, in contrast to other conditions associated with kidney injury (i.e. cardiac surgery, kidney transplantation, and contrast nephropathy), uNGAL concentration was only moderately elevated, which suggests that tubular damage, if it occurs, is of rather limited magnitude. 26, 27 . We demonstrated that the urinary biomarkers were strongly correlated with the UACR, the traditional marker of nephron damage, but not with creatinine, eGFR, or urea. It should be highlighted that serum and urinary concentrations of biomarkers may represent different aspects of nephron dysfunction. Serum accumulation may be related to reduced filtration function (with or without overproduction), while urinary concentration is more like a marker of impaired natriuresis and diuresis.
11 It should be emphasized that the analysis of urinary biomarkers in patients with HF is becoming an emerging and valuable field of research providing unique information. 28 Urinary concentration is mainly an outcome of local tubular synthesis in response to injury, whereas the serum concentration seems to be a result of wide systemic production (driven by inflammation, oxidative stress, and other factors), which can be only exacerbated by worse eGFR. 29, 30 Thus, these two 'pools' of biomarkers reflect different pathophysiological processes. Apart from the risk stratification and more accurate diagnosis, the analysis of novel biomarkers may lead to better understanding of the pathophysiology of the cardio-renal syndrome, which is a disorder with heterogeneous pathophysiology and multifactorial aetiology, and needs accurate diagnosis.
Study limitations
As the prevalence of true WRF was 10% in our group, we identified a relatively small number of such patients, and further studies are needed to characterize them better and to verify the role of novel urinary biomarkers in the diagnosis of true WRF. This may be particularly relevant for the future assessment of whether true WRF is independently associated with poor clinical outcomes.
. Chronic kidney disease is frequent in patients with chronic HF. In our population, 77% of patients had a history of chronic HF. As we do not have any data on renal function before hospitalization in our cohort, we are not able to distinguish between those with deterioration in renal function related to decompensation and those with chronic kidney disease which was further exacerbated during an episode of AHF. The MDRD equation was used to calculate the eGFR. Some authors suggest using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula which is more precise in the higher range of eGFR (>60 mL/min/1.73 m 2 ). 31 We used the CKD-EPI formula in the sensitivity analysis, which did not change the overall meaning of the results. Finally, we performed serial measurements of novel biomarkers after 24 and 48 h, which is the most vulnerable phase of hospitalization. We did not verify the levels of new biomarkers in the first 6-12 h, and such early determination might turn out to be more important for prediction of true WRF. Due to the limited size of the analysed population, our results need prospective evaluation in the context of the new definition of true WRF and the new biomarkers. Given ethnic differences in biomarker predictors of AHF, this will also require evaluation in different countries and ethnicities. 32 Medical treatment can lead to an increase in serum creatinine in patients with HF and may also be protective in patients with concomitant WRF; 33 however, it remains unclear whether treatment recommended in HF may affect an occurrence of true WRF and a release of novel urinary biomarkers. It is also advisable to arrange similar studies concerning other organ dysfunction, such as worsening liver function, as there is a possibility that other organ dysfunction episodes may be similarly true or false. 34 Not every deterioration in organ biomarkers is related to genuine organ damage. Laboratory disorders seen in AHF should always be evaluated in relation to clinical status and applied therapy.
Conclusion
In patients with AHF, an increase in the biomarkers of tubular damage, especially uNGAL, predicts development of true WRF. Elevated levels of uNGAL and uCysC in the first 2 days of hospital stay could be used to identify patients with a high risk of post-discharge mortality. To verify the utility of the novel biomarkers to characterize better those patients with true WRF, larger studies are needed, with a revised definition of WRF and with more frequent biomarker evaluation in the early phase of hospital stay to illustrate their dynamics.
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